RealTime Dynamix™: Psoriasis US Q4 2018 Spotlight

Real time dynamix

Spherix Global Insights’ fourth quarter update of RealTime Dynamix™: Psoriasis (US), which includes the feedback of 100 U.S. dermatologists, reveals that Ilumya will likely face an uphill battle for adoption. Conversely, Tremfya, the first IL-23 inhibitor to be FDA approved for the treatment of psoriasis, continues to grow, making it difficult for newcomer Ilumya to establish preference over Janssen’s agent. View complimentary data highlights from the most recent update of the quarterly series below.

Contact [email protected] for more information about the highlighted report or to see if your company already has access to our services in psoriasis.

All company, brand or product names and logos in this document are trademarks of their respective holders.